Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 879 results found since Jan 2013.

Small extracellular vesicle-mediated < em > ITGB6 < /em > siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biol Ther. 2022 Dec 31;23(1):173-185. doi: 10.1080/15384047.2022.2030622.ABSTRACTThe αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers. Here, we report that transcript levels of ITGB6 (encoding the β6 integrin subunit) are significantly increased in metastatic castrate-resistant androgen receptor-negative prostate tumors compared to androgen receptor-positive prostate tumors. In addition, the αVβ6 integrin protein levels are significantly elevated in androgen receptor-negative PrC...
Source: Cancer Biology and Therapy - February 21, 2022 Category: Cancer & Oncology Authors: Shiv Ram Krishn Vaughn Garcia Nicole M Naranjo Fabio Quaglia Christopher D Shields Maisha A Harris Andrew V Kossenkov Qin Liu Eva Corey Dario C Altieri Lucia R Languino Source Type: research

Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the alphaVbeta6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biol Ther. 2022 Dec 31;23(1):173-185. doi: 10.1080/15384047.2022.2030622.ABSTRACTThe αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers. Here, we report that transcript levels of ITGB6 (encoding the β6 integrin subunit) are significantly increased in metastatic castrate-resistant androgen receptor-negative prostate tumors compared to androgen receptor-positive prostate tumors. In addition, the αVβ6 integrin protein levels are significantly elevated in androgen receptor-negative PrC...
Source: Cancer Control - February 21, 2022 Category: Cancer & Oncology Authors: Shiv Ram Krishn Vaughn Garcia Nicole M Naranjo Fabio Quaglia Christopher D Shields Maisha A Harris Andrew V Kossenkov Qin Liu Eva Corey Dario C Altieri Lucia R Languino Source Type: research

Small extracellular vesicle-mediated < em > ITGB6 < /em > siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biol Ther. 2022 Dec 31;23(1):173-185. doi: 10.1080/15384047.2022.2030622.ABSTRACTThe αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers. Here, we report that transcript levels of ITGB6 (encoding the β6 integrin subunit) are significantly increased in metastatic castrate-resistant androgen receptor-negative prostate tumors compared to androgen receptor-positive prostate tumors. In addition, the αVβ6 integrin protein levels are significantly elevated in androgen receptor-negative PrC...
Source: Cancer Biology and Therapy - February 21, 2022 Category: Cancer & Oncology Authors: Shiv Ram Krishn Vaughn Garcia Nicole M Naranjo Fabio Quaglia Christopher D Shields Maisha A Harris Andrew V Kossenkov Qin Liu Eva Corey Dario C Altieri Lucia R Languino Source Type: research

Synergistic Silencing of Skp2 by siRNA Self ‐Assembled Nanoparticles as a Therapeutic Strategy for Advanced Prostate Cancer
Carrier-free delivery of siRNA targeting oncogenicSkp2 is achieved by self-assembly of siSkp2 with quercetin (Que) into nanoparticle. The constructed siSkp2/Que nanoparticles exhibit a synergistic silencing effect by simultaneous degradation of mRNA and protein ofSkp2, leading to apoptosis and proliferation inhibition in advanced prostate cancer cells both in vitro and in vivo. AbstractAdvanced prostate cancer, harboring multiple mutations of tumor suppressor genes, is refractory to conventional therapies. Knockout of theSkp2 gene blocks pRb/p53 doubly deficient prostate cancer in mice, which inspired the authors to develo...
Source: Small - February 19, 2022 Category: Nanotechnology Authors: Hong Liang, Fangming Zhang, Yannv Hong, Yue Wu, Huanzhang Xie, Chen Zhang, Zonghua Wang, Zhonglei Lu, Huanghao Yang Tags: Research Article Source Type: research

Loading of "cocktail siRNAs" into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer
Cancer Biol Ther. 2022 Dec 31;23(1):163-172. doi: 10.1080/15384047.2021.2024040.ABSTRACTExtracellular vesicles (EVs) are cell-derived, membranous nanoparticles that mediate intercellular communication by transferring biomolecules between cells. As natural vehicles, EVs may exhibit higher delivery efficiency, lower immunogenicity, and better compatibility than existing RNA carriers. A major limitation of their therapeutic use is the shortage of efficient, robust, and scalable methods to load siRNA of interest. Here, we report a novel strategy using polycationic membrane-penetrating peptide TAT to encapsulate siRNAs into EVs...
Source: Cancer Biology and Therapy - February 16, 2022 Category: Cancer & Oncology Authors: Yanjun Diao Gangqiang Wang Bingbing Zhu Zhuo Li Shan Wang Lijuan Yu Rui Li Weixiao Fan Yue Zhang Lei Zhou Liu Yang Xiaoke Hao Jiayun Liu Source Type: research

Silencing of TP73-AS1 impairs prostate cancer cell proliferation and induces apoptosis via regulation of TP73
CONCLUSIONS: Our findings provide novel evidence that suggests a chief regulatory role for the TP73-TP73-AS1 axis in prostate cancer development and progression, suggesting that the TP73/TP73-AS1 axis can be a promising diagnostic and therapeutic target for prostate cancer.PMID:35138524 | DOI:10.1007/s11033-022-07141-6
Source: Molecular Biology Reports - February 9, 2022 Category: Molecular Biology Authors: Ahmet Arslan Bahadir Batar Ebru Temiz Hilmi Tozkir Ismail Koyuncu Esra Bozgeyik Source Type: research

Small interfering RNA targeting N-cadherin regulates cell proliferation and migration in enzalutamide-resistant prostate cancer
Oncol Lett. 2022 Mar;23(3):90. doi: 10.3892/ol.2022.13210. Epub 2022 Jan 21.ABSTRACTEnzalutamide is one of the options for treating patients with castration-resistant or metastatic prostate cancer. However, a substantial proportion of patients become resistant to enzalutamide after a period of treatment. Cells in these tumors typically exhibit increased proliferative and migratory capabilities, in which N-cadherin (CDH2) appear to serve an important role. In the present study, by up- and downregulating the expression of CDH2, the possible effects of CDH2 on the prostate cancer cell line LNCaP were investigated. Male sex ho...
Source: Oncology Letters - February 7, 2022 Category: Cancer & Oncology Authors: Cheng-Hsin Lu Chun-Hsien Wu Pei-Fang Hsieh Chen-Yu Wu Wade Wei-Ting Kuo Chien-Hui Ou Victor Chia Hsiang Lin Source Type: research

Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation
CONCLUSIONS: In conclusion, down-regulation of FAP-α can inhibit the invasion and proliferation of prostate cancer. Our study provides a theoretical basis for the targeted treatment of prostate cancer.PMID:35129203 | DOI:10.14670/HH-18-430
Source: Histology and Histopathology - February 7, 2022 Category: Cytology Authors: Jiali An Dingkun Hou Lei Wang Lili Wang Yuanyuan Yang Haitao Wang Source Type: research